Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the efficacy of its drug setrusumab for treating Osteogenesis Imperfecta [1] Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Bailey v. Ultragenyx Pharmaceutical Inc. and covers investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1] - Allegations include that Ultragenyx executives made false statements about the reliability of data from the Phase III Orbit study, which purportedly minimized the risks of not achieving statistically significant results [1] - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance, leading to a stock price drop of over 25% [1] - A subsequent announcement on December 29, 2025, revealed that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, resulting in a further stock price decline of over 42% [1] Group 2: Company Background - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [1] - The company’s optimism regarding the Phase III Orbit study was reportedly misplaced, as it did not adequately communicate the risks associated with its Phase II results, which lacked a placebo control group [1] Group 3: Legal Process and Firm Information - The Private Securities Litigation Reform Act of 1995 allows investors who suffered losses during the class period to seek appointment as lead plaintiff in the lawsuit [1] - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1]